{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:06:52Z","timestamp":1767989212753,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Melasma is a challenging hyperpigmentation disorder affecting predominantly women with darker skin tones. Despite various treatments, achieving consistent and effective results remains difficult. Tranexamic acid (TXA) has emerged as a promising therapeutic agent, particularly through intradermal injections, but its optimal concentration, delivery method, and combination therapies remain unclear. In this study, the authors aim to evaluate the efficacy and safety of injectable TXA, focusing on its use alone and in combination with other treatments, such as hydroquinone, for melasma. A network meta-analysis of 9 randomized controlled trials was conducted, involving 358 participants. Data on melasma subtype, TXA concentration, delivery method, and treatment outcomes (Melasma Area and Severity Index [MASI] scores) were extracted. Statistical analysis was performed using a random-effects model, assessing both direct and indirect comparisons. The combination of TXA and 4% hydroquinone showed the most significant improvement in MASI scores compared with other interventions, demonstrating superior efficacy. Adverse effects were mild and transient, including injection-site pain and erythema, underscoring a favorable safety profile. Injectable TXA, especially in combination with hydroquinone, is an effective treatment for melasma. Standardized protocols and long-term studies are needed to optimize its use.<\/jats:p>\n               <jats:p>Level of Evidence: 3 (Therapeutic)<\/jats:p>\n               <jats:p\/>","DOI":"10.1093\/asj\/sjaf097","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T07:23:34Z","timestamp":1748244214000},"page":"947-956","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Efficacy and Safety of Injectable Tranexamic Acid Combination Therapies for Melasma: A Network Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3180-8876","authenticated-orcid":false,"given":"Houriah","family":"Nukaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Abdullah S","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Alhawsawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Ridha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-2113","authenticated-orcid":false,"given":"Malika","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruaa","family":"Alharithy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulhadi","family":"Jfri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025081721572665300_sjaf097-B1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13555-017-0194-1","article-title":"Melasma: an up-to-date comprehensive review","volume":"7","author":"Ogbechie-Godec","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025081721572665300_sjaf097-B2","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/archderm.131.12.1453","article-title":"Melasma. Etiologic and therapeutic considerations","volume":"131","author":"Grimes","year":"1995","journal-title":"Arch Dermatol"},{"key":"2025081721572665300_sjaf097-B3","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.3390\/ijerph20227068","article-title":"The effect of melasma on the quality of life in people with darker skin types living in Durban, South Africa","volume":"20","author":"Mpofana","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"2025081721572665300_sjaf097-B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32133.x","article-title":"Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial","author":"Lee","year":"2006","journal-title":"Dermatol Surg."},{"key":"2025081721572665300_sjaf097-B5","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20143063","article-title":"Melasma: a clinical and epidemiological review","author":"Handel","year":"2014","journal-title":"An Bras Dermatol"},{"key":"2025081721572665300_sjaf097-B6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.0007-0963.2001.04556.x","article-title":"Melasma: histopathological characteristics in 56 Korean patients","volume":"146","author":"Kang","year":"2002","journal-title":"Br J Dermatol"},{"key":"2025081721572665300_sjaf097-B7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/s0190-9622(81)70071-9","article-title":"Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study","volume":"4","author":"Sanchez","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"2025081721572665300_sjaf097-B8","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/jcpt.13430","article-title":"Efficacy and safety of tranexamic acid in the treatment of adult melasma: an updated meta-analysis of randomized controlled trials","volume":"46","author":"Feng","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2025081721572665300_sjaf097-B9","doi-asserted-by":"publisher","first-page":"1683414","DOI":"10.1155\/2018\/1683414","article-title":"Tranexamic acid for adults with melasma: a systematic review and meta-analysis","volume":"2018","author":"Zhang","year":"2018","journal-title":"Biomed Res Int"},{"key":"2025081721572665300_sjaf097-B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/2349-5847.196295","article-title":"Tranexamic acid: an emerging depigmenting agent","volume":"3","author":"George","year":"2016","journal-title":"Pigm Int"},{"key":"2025081721572665300_sjaf097-B11","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1111\/jocd.15242","article-title":"Medical therapies for melasma","volume":"21","author":"Mahajan","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"2025081721572665300_sjaf097-B12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025081721572665300_sjaf097-B13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2025081721572665300_sjaf097-B14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025081721572665300_sjaf097-B15","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2025081721572665300_sjaf097-B16","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1002\/hsr2.537","article-title":"Efficacy of intradermal injection of tranexamic acid and ascorbic acid versus tranexamic acid and placebo in the treatment of melasma: a split-face comparative trial","volume":"5","author":"Pazyar","year":"2022","journal-title":"Health Sci Rep"},{"key":"2025081721572665300_sjaf097-B17","doi-asserted-by":"publisher","first-page":"e1636","DOI":"10.1002\/hsr2.1636","article-title":"Evaluation of the effectiveness of microneedling with tranexamic acid in comparison with microneedling with vitamin C in the treatment of melasma: a prospective and single-blind clinical trial","volume":"6","author":"Pazyar","year":"2023","journal-title":"Health Sci Rep"},{"key":"2025081721572665300_sjaf097-B18","doi-asserted-by":"publisher","first-page":"8350317","DOI":"10.1155\/2018\/8350317","article-title":"Evaluation of therapeutic efficacy and safety of tranexamic acid local infiltration in combination with topical 4% hydroquinone cream compared to topical 4% hydroquinone cream alone in patients with melasma: a split-face study","volume":"2018","author":"Tehranchinia","year":"2018","journal-title":"Dermatol Res Pract"},{"key":"2025081721572665300_sjaf097-B19","first-page":"35","article-title":"Intradermal injection of 100 mg tranexamic acid versus topical 4% hydroquinone for the treatment of melasma: a randomized, controlled trial","volume":"16","author":"Pazyar","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025081721572665300_sjaf097-B20","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00403-023-02580-y","article-title":"Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study","volume":"315","author":"Abd Elraouf","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2025081721572665300_sjaf097-B21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jocd.13537","article-title":"Micro-needling versus fractional carbon dioxide laser for delivery of tranexamic acid in the treatment of melasma: a split-face study","volume":"20","author":"Mekawy","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"2025081721572665300_sjaf097-B22","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1111\/jocd.14440","article-title":"Microneedling-assisted topical tranexamic acid solution versus 4% hydroquinone for treating melasma: a split-face randomized study","volume":"20","author":"Zaky","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"2025081721572665300_sjaf097-B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/jocd.13112","article-title":"Comparing the efficacy of Myjet-assisted tranexamic acid and vitamin C in treating melasma: a split-face controlled trial","volume":"19","author":"Zhao","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"2025081721572665300_sjaf097-B24","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1111\/jocd.13392","article-title":"Efficacy of microneedling plus topical 4% tranexamic acid solution vs 4% hydroquinone in the treatment of melasma: a single-blind randomized clinical trial","volume":"19","author":"Meymandi","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"2025081721572665300_sjaf097-B25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5021\/ad.2014.26.3.401","article-title":"Regression of melasma with platelet-rich plasma treatment","volume":"26","author":"Cay\u0131rl\u0131","year":"2014","journal-title":"Ann Dermatol"},{"key":"2025081721572665300_sjaf097-B26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40257-017-0263-3","article-title":"Tranexamic acid in the treatment of melasma: a review of the literature","volume":"18","author":"Perper","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2025081721572665300_sjaf097-B27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2340\/00015555-2668","article-title":"Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review","volume":"97","author":"Kim","year":"2017","journal-title":"Acta Derm Venereol"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjaf097\/63636807\/sjaf097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/9\/947\/63636807\/sjaf097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/9\/947\/63636807\/sjaf097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T01:57:33Z","timestamp":1755482253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/45\/9\/947\/8180359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjaf097","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,1]]}}}